Senti Biosciences, Inc. (NASDAQ:SNTI) Short Interest Update

Senti Biosciences, Inc. (NASDAQ:SNTI) saw a significant decline in short interest in the month of December. As of December 31st, there was short interest totalling 63,600 shares, a decline of 38.8% from the December 15th total of 103,900 shares. Based on an average trading volume of 2,230,000 shares, the short-interest ratio is presently 0.0 days. Approximately 2.2% of the shares of the company are short sold.

Senti Biosciences Stock Up 10.0 %

NASDAQ SNTI traded up $0.38 during trading hours on Thursday, hitting $4.19. The company had a trading volume of 457,682 shares, compared to its average volume of 106,567. The firm has a market cap of $19.23 million, a P/E ratio of -0.27 and a beta of 2.42. Senti Biosciences has a fifty-two week low of $1.52 and a fifty-two week high of $16.94. The business has a fifty day simple moving average of $3.93 and a 200-day simple moving average of $3.01.

Wall Street Analysts Forecast Growth

Separately, Chardan Capital reaffirmed a “buy” rating and set a $10.00 target price on shares of Senti Biosciences in a report on Monday, December 2nd.

About Senti Biosciences

Senti Biosciences, Inc operates as a preclinical biotechnology company that develops next-generation cell and gene therapies engineered with its gene circuit platform technologies for various diseases. Its lead product candidates utilize allogeneic chimeric antigen receptor natural killer (CAR-NK) cells outfitted with its gene circuit technologies in various oncology indications.